Related Experiment Video
Updated: Jan 9, 2026
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis
Ashritha A Udupa1, Pratibha Todur2, Souvik Chaudhuri1
1Department of Critical Care, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Aim And Background:
Acute respiratory distress syndrome (ARDS) is a life-threatening condition with a high mortality rate despite advances in supportive care. Aviptadil, a synthetic analogue of vasoactive intestinal peptide (VIP), exhibits anti-inflammatory potential and cytoprotective effects that may improve pulmonary function. However, its role in improving survival among ARDS patients remains uncertain. This systematic review and meta-analysis aimed to evaluate the effectiveness of aviptadil in improving survival and oxygenation outcomes in ARDS.
Methodology:
A comprehensive search was conducted across six databases-PubMed, Scopus, Embase, Google Scholar, Cochrane Library, and Web of Science-up to October 2025. Two investigators independently screened eligible studies. Descriptive synthesis and meta-analysis were performed using a random-effects model. The risk of bias (RoB) was assessed with the RoB 2 tool for randomized controlled trials (RCTs) and the Joanna Briggs Institute (JBI) tool for case series.
Results:
The systematic review included nine studies (two RCTs and seven case series) with a total of 665 patients, 361 of whom received aviptadil. Meta-analysis of the two RCTs yielded a pooled prevalence of survival of 0.71 [95% confidence interval (CI): 0.53-0.87]. The survival odds ratio (OR) comparing aviptadil to placebo was 1.01 (95% CI: 0.72-1.42, p = 0.93), indicating no significant benefit. Across the case series, 48 of 54 patients (88.9%) survived following aviptadil therapy, demonstrating consistent improvements in oxygenation and reductions in inflammatory markers.
Conclusion:
Aviptadil may have a physiological role in improving oxygenation and reducing inflammation in ARDS; however, current evidence does not indicate a significant survival benefit. Larger, well-designed RCTs are needed to clarify its therapeutic potential.
How To Cite This Article:
Udupa AA, Todur P, Chaudhuri S, Gupta N, Bhat VR, Nagendra D, et al. Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis. Indian J Crit Care Med 2025;29(11):942-953.
More Related Videos
Related Concept Videos
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:23Acute Respiratory Failure-IV
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...